AIDS activists in Uganda are worried about a proposed reduction in the country’s health budget, as Parliament begins “a months-long budgeting process for the … next fiscal year,” VOA News reports. “AIDS activists have expressed concern that Uganda’s proposed budget for the next fiscal year includes a six percent cut in health funding to $307.5 million,” which “is less than 10 percent of the country’s overall budget,” the news service writes. Joshua Wamboga of The AIDS Support Organization said a lack of financial commitment from the government could undermine efforts to fight HIV/AIDS in the country, VOA notes, adding, “Government officials said the cut to the health budget reflects construction projects in that sector that have been completed and no longer require funding.” According to VOA, “The budget is months away from being finalized and activists hope there is still time to increase funds” (Green, 5/15).
Estimated 740,000 Deaths In Africa Averted Between 2004-2008 In Association With PEPFAR, Study Shows
“The lives of more than 740,000 people in nine African countries were saved between 2004 and 2008 by the U.S. President’s Emergency Plan for AIDS Relief [PEPFAR],” according to a study conducted by Stanford University School of Medicine researchers and published in the Journal of the American Medical Association (JAMA) on Wednesday, HealthDay News reports (3/15). “The study is the first to show a decline in all-cause mortality related to the program,” a Stanford press release notes, adding, “To measure the impact of the program, [Eran Bendavid, assistant professor of medicine at Stanford,] and his colleagues analyzed health and survival information for more than 1.5 million adults in 27 African countries, including nine countries where PEPFAR has focused its efforts” (Richter, 5/10). According to the study, “an estimated total of 740,914 all-cause adult deaths were averted between 2004 and 2008 in association with PEPFAR,” and “[i]n comparison, PEPFAR was associated with an estimated 631,338 HIV-specific deaths averted during the same period,” a JAMA press release states, noting that “all-cause adult mortality declined more in African countries in which … PEPFAR operated more intensively” (5/15).
GlobalPost reports on the GBCHealth Conference, which took place in New York City on Monday and where “panelists at a session titled ‘AIDS@30’ were asked how they would fulfill U.S. Secretary of State Hillary Clinton’s call late last year for an ‘AIDS-free generation.'” According to the news service, “Ambassador Eric Goosby, the U.S. global AIDS coordinator, said the key will likely be a combination HIV prevention strategy” that “includes expansion of treatment to help prevent new infections; major scale-up of male circumcision; and treating all HIV-positive pregnant women to end the transmission of HIV from mother to child.” GlobalPost adds, “Michel Sidibe, UNAIDS executive director, said the way to defeat AIDS had to include more financial contributions from developing countries.” GlobalPost quotes several other conference attendees (Donnelly, 5/15).
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences’ antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus. According to the New York Times, “Such a pill has long been a goal of research, something that might help stem a global epidemic that is still causing two million new worldwide cases each year, including 50,000 in the United States” (Grady, 5/14). The Financial Times says some have concerns over the real world efficacy of the drug; whether its approval would encourage reckless behavior, such as not using condoms; side effects that might require additional treatment; the development of drug-resistant HIV strains; and the cost of the drug.
NPR's 'All Things Considered' Examines How Greater Acceptance Of India's Gay Community Helps HIV Fight
NPR’s “Shots” blog includes an “All Things Considered” story that examines how “a 2009 benchmark ruling in Delhi’s High Court,” which “struck down a 148-year-old law known as Section 377, a holdover from British colonial rule that made homosexual acts illegal,” has led to a wider level of HIV outreach to Mumbai’s gay community. Vivek Anand, CEO of the Humsafar Trust, “which provides free HIV tests and other health services to Mumbai’s gay community,” said the ruling has helped health workers gain a better understanding of HIV prevalence among India’s gay population, the blog notes.
Botswana, Lesotho, Swaziland, Zambia, and Zimbabwe all have launched national campaigns urging men to undergo circumcision to help reduce their risk of contracting or transmitting HIV infection, but “all the countries are lagging far behind their targets,” Agence France-Presse reports in an article focusing on efforts in Botswana. A three-year-old campaign in Botswana, aimed at convincing 460,000 men to get circumcised, “has reached only seven percent of this figure,” the news agency notes, adding, “Now the government has enlisted the help of top musicians and launched a new series of advertisements touting ‘safe male circumcision’ as a lifeline.”
The PBS NewsHour on Friday featured an interview of Anthony Fauci, director of the NIH National Institute of Allergy and Infectious Diseases (NIAID), by Senior Correspondent Ray Suarez, in which they discussed an FDA panel’s recommendation that the antiretroviral Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus. If approved, Truvada “can be potentially very effective” as a prevention modality among specific populations at high risk of contracting HIV, Fauci said, according to the interview. Fauci also discussed the medication’s cost and concerns about adherence to the drug regimen, PBS notes (Suarez, 5/11).
“In the last 20 years, the world has saved more than 50 million children’s lives and reduced maternal mortality by one-third,” “accomplishments [that] have been the result of good science, good management, bipartisan political support, the engagement of USAID and many other U.S. Government agencies, and the participation of faith-based organizations, civil society, and the private sector,” according to a summary of USAID’s “Global Health and Child Survival: Progress Report to Congress 2010-2011.” The summary states, “With prospects for ending preventable child and maternal deaths, creating an AIDS-free generation, and laying the foundations for universal health coverage, future generations will look back at this period as a turning point in the history of global health” (5/10).
International AIDS Conference To Highlight International, Domestic U.S. AIDS Policies, Politico Reports
When the International AIDS Conference convenes in Washington in July, the first time the U.S. will host the conference in more than 20 years, “it will signal that the U.S. has brought its HIV policies into better alignment with the principles it advocates abroad,” Politico reports, referencing the lifting of the “Helms rule” — which denied U.S. visas to people who are HIV positive — in 2009. “The policy was especially painful to advocates because U.S. scientific and financial investments are largely responsible for stemming the tide of the epidemic around the world,” the news service writes. “But the meeting will also highlight other ways that the U.S. has fallen short, advocates say,” the news service writes, noting that the U.S. epidemic is not slowing. Politico discusses the successes and criticisms of several domestic HIV/AIDS initiatives under the Obama administration (Feder, 5/13).
In this post on the Center for Global Development’s (CGD) “Global Health Policy” blog, Research Fellow Victoria Fan, Director of Global Health Policy Amanda Glassman, and Research Assistant Rachel Silverman of CGD examine what they call the “serious limitations” of a study published recently in the American Journal of Tropical Medicine & Hygiene that looked at the impact of HIV/AIDS funding on Rwanda’s health system. After describing several “shortcomings,” they write, “We understand that the authors likely suffered from significant data constraints; likewise, we recognize the enormous empirical challenges in demonstrating system-wide effects at the national level. Still, it remains important to carefully state results and recognize the limitations of one’s research.” They conclude, “The jury is still out on whether HIV/AIDS funding has displaced or improved efforts on other disease control priorities” (5/10).